broncho-munal p 3,5 mg cietās kapsulas
sandoz d.d., slovenia - liofilizēts baktēriju lizāts - kapsula, cietā - 3,5 mg
broncho-munal 7 mg cietās kapsulas
sandoz d.d., slovenia - liofilizēts baktēriju lizāts - kapsula, cietā - 7 mg
inomax
linde healthcare ab - slāpekļca oksīds - hypertension, pulmonary; respiratory insufficiency - other respiratory system products - inomax, kopā ar elpināšanas atbalsta un citu attiecīgo aktīvo vielu, ir norādīts:ārstēšanā jaundzimušajiem ≥34 grūtniecības nedēļas ar hipoksiskiem elpošanas mazspēja, kas saistīta ar klīnisko vai echocardiographic pierādījumus par plaušu hipertensiju, lai uzlabotu apgādi ar skābekli un mazina nepieciešamību extracorporeal membrānu apgādi ar skābekli;kā daļa no ārstēšanas, peri - un pēcoperācijas plaušu hipertensiju pieaugušajiem, gan jaundzimušajiem, zīdaiņiem un maziem bērniem, bērniem un pusaudžiem, vecums 0-17 gadi kopā, lai sirds operācija, lai selektīvi samazināt plaušu arteriālā spiediena un uzlabot tiesības kambara funkcijas un skābekļa.
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - cistiskā fibroze - other respiratory system products - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
orkambi
vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistiskā fibroze - other respiratory system products - orkambi tabletes ir indicēts, lai ārstētu cistiskā fibroze (cf) pacientiem vecumā no 6 gadiem un vecākiem, kas ir homozygous par f508del cftr mutācija gēnu. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistiskā fibroze - other respiratory system products - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistiskā fibroze - other respiratory system products - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
slāpekļa (ii) oksīds elme messer 800 ppm (v/v) medicīniskā gāze, saspiesta
elme messer l, sia, latvia - slāpekļca oksīds - medicīniskā gāze, saspiesta - 800 ppm (v/v)
cefaximin-l suspensija ievadīšanai tesmenī
fatro s.p.a., itālija - rifaximin, cephacetrile sodium - suspensija ievadīšanai tesmenī - laktējošas govis
cefaximin-l emulsija ievadīšanai tesmenī
fatro s.p.a., itālija - rifaximin, cephacetrile sodium - emulsija ievadīšanai tesmenī - govis